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2Quorum sensing (QS) is commonly used in microbial communities and 
some unicellular parasites to coordinate group behaviours
1,2
. An 
example is Trypanosoma brucei that causes Human African 
trypanosomiasis, as well as the livestock disease, nagana. 
Trypanosomes are spread by tsetse flies, transmission being enabled 
by cell-cycle arrested ‘stumpy forms’ that are generated in a density-
dependent manner in mammalian blood. QS is mediated through a small 
(<500 Da), non-proteinaceous, stable but unidentified ‘stumpy induction 
factor’
3
, whose signal response pathway has been identified. Although 
QS is characterised in T. brucei, co-infections with other trypanosome 
species (T. congolense, T. vivax) are common in animals, generating the 
potential for interspecies interactions. Here, we show that T. 
congolense exhibits density-dependent growth control in vivo and 
conserves QS-regulatory genes, of which one can complement a T. 
brucei QS signal-blind mutant to restore stumpy formation. Thereafter 
we demonstrate that T. congolense-conditioned culture medium 
promotes T. brucei stumpy formation in vitro, dependent upon integrity 
of the QS signalling pathway. Finally, we show that, in vivo, co-infection 
with T. congolense accelerates differentiation to stumpy forms in T. 
brucei, this also being QS dependent. These cross-species interactions 
have important implications for trypanosome virulence, transmission, 
competition and evolution in the field.
Trypanosoma brucei, Trypanosoma congolense and Trypanosoma 
vivax are African trypanosome species that can infect game animals and 
livestock, with a co-infection frequency of up to 25% where analysed
4-7
. All 
three species are spread by tsetse flies but undergo distinctive
developmental paths within the arthropod vector
8
. Furthermore, only 
Trypanosoma brucei is reported to undergo developmental transformation in 
the bloodstream of mammalian hosts in preparation for transmission, 
generating ‘stumpy forms’ that are G1 arrested and morphologically distinct
from ‘slender forms’ that proliferate to establish each wave of parasitaemia
9
. 
3Other trypanosome species are described as monomorphic, or have ill-
defined morphological heterogeneity in the historical literature
10-12
, although 
T. vivax can accumulate in a G1 arrested form
13
. To determine whether T.
congolense exhibits density dependent cell-cycle arrest in the mammalian 
bloodstream, six mice infected with T. congolense ILTat3000 were monitored
for their kinetoplast (K) and nuclear (N) configuration
14
, a cytological indicator 
of cell cycle position. Analysis over the first 14 days of infection demonstrated 
that parasite number had a significant negative effect on the proportion of 
proliferating (2K1N, 2K2N) cells (general linear model, p=0.001) (Figure 1a) 
such that parasites accumulated with a 1K1N configuration in individual 
infections when their numbers exceeded approximately 8x10
7
/ml 
(Supplementary Figure 1). Although this was not associated with an 
accompanying morphological transition equivalent to T. brucei stumpy 
formation (Figure 1b-d), BLAST and reciprocal BLAST analysis of the 
genome of T. congolense identified potential orthologues of a characterised 
set of 25 T. brucei genes required for stumpy formation
15
(Supplementary
Table 1), there being a similar number in the T. vivax genome. Hence T.
congolense demonstrated density-dependent cell-cycle arrest in vivo and 
encodes predicted orthologues of components of the T. brucei stumpy 
formation pathway.
To explore conservation of the signalling pathway responsible for 
stumpy formation between T. congolense and T. brucei, functional 
complementarity was examined (Figure 2). Null mutants for Tb927.9.4080 
(‘TbHYP2’, previously identified as a component of the T. brucei QS response 
pathway
15
; Supplementary table 2 and Supplementary Figure 2) were initially 
generated in pleomorphic T. brucei EATRO 1125 by sequential allelic
replacement (T. brucei AnTat1.1 90:13 TbHYP2; Supplementary Figure 3).
As expected for a QS signalling pathway component, TbHYP2 null mutants
lost the capacity for growth control in vivo (Supplementary Figure 4). They 
also did not express the PAD1 marker for stumpy forms
16
 (Supplementary
Figure 4) and, when harvested and exposed to the developmental trigger cis-
aconitate, differentiated to the next life-cycle stage (procyclic forms) less 
efficiently than wild type parasites as assessed by expression of the procyclic 
4surface protein EP procyclin and proliferation (Supplementary Figure 4).
Thereafter, the TbHYP2 null mutants were engineered (Figure 2a) for 
doxycycline-inducible ectopic expression of the T. congolense orthologue of 
TbHYP2 (TcIL3000.0.19510, ‘TcHYP2’; E value: 5.9e-262, 45% identity, 58% 
similarity to TbHYP2; Supplementary Table 1). Figure 2b shows that upon 
inducible expression of TcHYP2, there was slowed progression of the 
parasitaemia in vivo, potentially linked to either a premature development to 
stumpy forms caused by overexpression of the QS-signal pathway orthologue 
or a dominant negative consequence of TcHYP2 expression. Supporting the 
former, those parasites induced to express TcHYP2 exhibited PAD1 
expression, whilst uninduced parasites remained PAD1 negative (Figure 2c). 
Further, when exposed to cis-aconitate the induced parasites expressed EP 
procyclin more effectively than the uninduced lines after 4h and 24h (Figure 
2d; p<0.0001 and p=0.0082 respectively). Combined these assays 
demonstrated that TcHYP2 can restore stumpy formation in a T. brucei
TbHYP2 null mutant, demonstrating functional complementarity between the 
genes.
Next, to explore interspecies cross talk in QS signals, the capacity for 
T. congolense to release a signal capable of inducing stumpy formation in T.
brucei was tested. Initially, pleomorphic T. brucei (EATRO 1125 AnTat1.1
90:13; capable of stumpy formation), monomorphic T. brucei (Lister 427 cells; 
incapable of stumpy formation) or culture-adapted T. congolense cells
(ILTat3000) were incubated in the presence of 50% or 75% conditioned 
medium from T. congolense culture (harvested from a T. congolense culture 
that had proliferated to 6x10
6
/ml after 3 days without passage). These 
parasite species grow optimally in different culture media but T. brucei can
grow effectively in TcN medium (75% TcBSF3 T. congolense growth 
medium
17
plus 25% HMI-9 T. brucei culture medium
18
). Supplementary Figure 
5a demonstrates that T. congolense grew uninterrupted in the presence of its 
own conditioned medium (‘TcCM’), demonstrating it could still support active 
proliferation uninhibited by the accumulation of toxic metabolites. In contrast,
T. brucei showed reduced growth with TcCM, this being more pronounced
with the pleomorphic line than the monomorphic line (Supplementary Figure 
55b, 5c). To assess whether this reflected a progression to stumpy formation
in pleomorphic cells, a reporter line was exploited with the chloramphenicol
acetyl transferase (CAT) gene expressed under the control of the PAD1 
3’UTR that governs its stumpy-specific gene expression
19
. In this case, TcCM
reduced growth (Figure 3a) and generated a 2.1fold (p=0.0002) increase in 
activation of the CAT reporter after 2 days compared to TcN, equivalent to 
the activation generated by T. brucei AnTat1.1 90:13 conditioned medium
(TbCM; 1.9-fold, p=0.0006) (Figure 3b). To explore whether the CAT-reporter 
response was mediated via the QS-signalling pathway, the same analysis 
was carried out using a cell line containing the CAT-PAD 3’UTR reporter 
construct but which was also capable of inducible RNAi of TbHYP2 (T. brucei
AnTat1.1 90:13 CAT-PAD TbHYP2 RNAi). When exposed to conditioned 
medium from T. brucei (TbCM, Figure 3c) or T. congolense (TcCM, Figure 
3d) for 48h and 72h, CAT reporter expression was significantly reduced upon
TbHYP2 RNAi compared to cells where TbHYP2 RNAi was not induced 
(TcCM at 48h, p=0.0009; TbCM at 48h, p<0.0001). Cell cycle arrest in 
response to TbCM and TcCM was also reduced upon TbHYP2 RNAi 
(Supplementary Figure 6). Confirming this was mediated through a QS 
response, a CAT reporter controlled by the 3’UTR of the constitutively-
expressed T. brucei aldolase gene was not significantly affected by TbHYP2 
RNAi when exposed to TbCM or a cell permeable mimic of the QS signal, 8-
pCPT-cAMP
20
 (Supplementary Figure 7). Hence, T. congolense conditioned 
medium, as well as T. brucei conditioned medium, can promote growth arrest 
and activation of stumpy reporter gene expression in pleomorphic T. brucei in 
vitro, this being mediated through the QS signalling pathway. In contrast, 
culture-adapted T. congolense did not show growth inhibition in T. brucei
conditioned medium containing QS-signal activity sufficient to arrest T. brucei
(Supplementary Figure 5d, 5e). It remains to be established whether T. 
congolense are not responsive to the T. brucei QS-signal or if this is a 
consequence of the culture-adapted T. congolense line used in the in vitro
experiments, which have been subject to long term passage. Unlike T. brucei
conditioned medium, 8-pCPT-cAMP could inhibit T. congolense growth in 
vitro, supporting the conservation of a QS signalling pathway between the 
6species, although the effect was less pronounced than with T. brucei
(Supplementary Figure 5f, 5g).
Having demonstrated the potential for cross-talk in QS signals 
between T. congolense and T. brucei in vitro, we examined whether the same 
response was detectable in co-infections between these species in vivo. To 
enable unambiguous identification of T. brucei in the mixed infection, we 
generated a T. brucei pleomorphic line encoding a Ty1 epitope tagged PFRA
protein (T. brucei AnTat1.1 90:13 PFR-Ty1)
21
. This allowed flagellar staining
to distinguish T. brucei from T. congolense, with simultaneous co-labelling
with PAD1 antibody and morphological analysis permitting quantitation of 
stumpy formation (Figure 4a). Infections were initiated with T. congolense
followed, on day 4 post-infection, with a super-infection with T. brucei
(Supplementary Figure 8a). Control infections involving either T. congolense
or T. brucei alone were analysed in parallel. The contribution of each species
to the overall parasite load was then determined by scoring cell number and 
PFR labelling (Figure 4b), as was T. brucei PAD1 expression (Figure 4c) and 
cell-cycle status (Supplementary Figure 9). In the presence of a co-infection 
with T. congolense, T. brucei generated more PAD1-positive cells at a lower 
overall density of T. brucei than in T. brucei infections alone (Figure 4c).
Thus, 50% of T. brucei cells were PAD1-positive in the co-infection compared 
with <10% in the mono-infection (p=0.0044), despite the T. brucei parasites 
comprising only a small proportion of the total parasite load, which was 
similar in the single species and mixed species infections (1x10
8
cells/ml; 
Supplementary Figure 8a). Furthermore, although comprising only a minority
of the overall parasitaemia in the co-infection (Figure 4b), the T. brucei
parasites had assumed a stumpy morphology and exhibited an accumulation 
of cells with a 1 kinetoplast, 1 nucleus configuration (p=0.015; Supplementary
Figure 9). To confirm that T. brucei stumpy formation was mediated via the 
QS-signalling pathway, co-infection was repeated using a PFR-epitope 
tagged T. brucei line capable of RNAi-mediated silencing of TbHYP2 under 
doxycycline regulation (T. brucei AnTat1.1 90:13 PFR-Ty1 TbHYP2 RNAi). 
Effective TbHYP2 silencing in this cell line was confirmed at the RNA level 
(Figure 4d), this being expected to inhibit differentiation to stumpy forms in 
7vivo. When co-infected with T. congolense (Supplementary Figure 8b, Figure 
4e), in the absence of TbHYP2 silencing, T. brucei stumpy formation was 
accelerated (Figure 4f) confirming the outcome with T. brucei AnTat1.1 90:13 
PFR-Ty1 cells (Figure 4c). However, with TbHYP2 silencing, the prevalence 
of PAD1-positive T. brucei cells was significantly less (p<0.0001) (Figure 4f, 
Supplementary Figure 10) as was the accumulation of cells with 1K1N
(p=0.007; Supplementary Figure 11), despite equivalent numbers of T. brucei
in each infection. Hence, co-infection with T. congolense induces T. brucei to 
generate stumpy forms at low relative parasitaemia, with dependence upon 
integrity of the T. brucei QS signalling pathway demonstrating that this is 
mediated through QS cross-talk between the species in vivo.
In combination, our results have established, firstly, that T. congolense
is capable of density sensing in vivo, generating cell-cycle arrested forms 
akin to the stumpy forms of T. brucei, albeit without significant morphological 
transformation. Secondly, and consistent with this, the genome of the 
parasite encodes many molecules with similarity to components previously 
implicated in T. brucei QS responses, at least one of which can functionally 
complement a T. brucei null mutant to rescue stumpy formation. Moreover, 8-
pCPT-cAMP which mimics the QS signal in T. brucei, also promotes growth 
inhibition in T. congolense supporting conservation of the signalling pathway. 
Finally, we have demonstrated that T. congolense can generate a QS signal
that drives T. brucei stumpy formation in vitro and during co-infections, and 
that this effect is lost when the T. brucei QS signalling pathway is silenced, 
demonstrating transduction via the same molecular pathway as the T. brucei
QS signal. This demonstrates the capacity for inter-species QS between 
Trypanosoma congolense and Trypanosoma brucei in simultaneously 
infected hosts. Interestingly, our results provide clear evidence of T. 
congolense signalling to T. brucei but the converse was less obvious. 
Whether this indicates that signalling is unidirectional or whether our culture 
adapted T. congolense line are less sensitive to the QS signal remains to be 
established.
Trypanosome infections are sustained long-term in mammalian hosts
in the field, such that the capacity for interaction within and between species
8in co-infections has the potential to generate distinct evolutionary 
responses
22,23
. For example, the production of a co-received QS signal may
favour a pre-existing parasite population by preventing a secondary incoming
trypanosome species proliferating and so establishing, a feature described in 
malaria infections
24,25
. Reduced sensitivity to the shared QS signal may also
be selected in the context of an established co-infection to improve 
competitive fitness. Finally, if production of the QS signal was resource 
costly, cheats that produce less signal could exploit that of the co-infecting 
parasites to assist their transmissibility
26,27
. These scenarios may each select
parasites whose capacity for virulence and transmissibility is adapted to the 
presence of a competing species. However, if transferred to naive hosts
without competitors, parasites adapted for co-infection might exhibit a 
different infection dynamic, potentially exhibiting enhanced virulence through 
their reduced sensitivity to QS signals. As well as T. brucei brucei, that can 
only infect animals, livestock and game animals are the long-term reservoir of 
human infective Trypanosoma brucei rhodesiense
28
 and, potentially,
Trypanosoma brucei gambiense. Where human infective T. brucei coexist 
with T. congolense, the transition from long-term maintenance in a co-
infected game reservoir into a monospecies infection in a human host may 
contribute, with host factors and other parasite factors, to the variability in 
parasite burden generated by different parasite isolates
29,30
.
9References
1. Brown, S.P. and A. Buckling.A social life for discerning microbes, Cell, 
2008. 135(4): p. 600-3.
2. Leggett, H.C., S.P. Brown, and S.E. Reece.War and peace: social 
interactions in infections, Philos Trans R Soc Lond B Biol Sci, 2014. 
369(1642): p. 20130365.
3. Vassella, E., B. Reuner, B. Yutzy, and M. Boshart.Differentiation of 
African trypanosomes is controlled by a density sensing mechanism 
which signals cell cycle arrest via the cAMP pathway, Journal of Cell 
Science, 1997. 110: p. 2661-2671.
4. Auty, H., N.E. Anderson, K. Picozzi, T. Lembo, J. Mubanga, R. Hoare, 
R.D. Fyumagwa, B. Mable, L. Hamill, S. Cleaveland, et 
al.Trypanosome diversity in wildlife species from the serengeti and 
Luangwa Valley ecosystems, PLoS Negl Trop Dis, 2012. 6(10): p. 
e1828.
5. Cox, A.P., O. Tosas, A. Tilley, K. Picozzi, P. Coleman, G. Hide, and 
S.C. Welburn.Constraints to estimating the prevalence of trypanosome 
infections in East African zebu cattle, Parasit Vectors, 2010. 3: p. 82.
6. Takeet, M.I., B.O. Fagbemi, M. De Donato, A. Yakubu, H.E. Rodulfo, 
S.O. Peters, M. Wheto, and I.G. Imumorin.Molecular survey of 
pathogenic trypanosomes in naturally infected Nigerian cattle, Res 
Vet Sci, 2013. 94(3): p. 555-61.
7. Pinchbeck, G.L., L.J. Morrison, A. Tait, J. Langford, L. Meehan, S. 
Jallow, J. Jallow, A. Jallow, and R.M. Christley.Trypanosomosis in The 
Gambia: prevalence in working horses and donkeys detected by whole 
genome amplification and PCR, and evidence for interactions between 
trypanosome species, BMC Vet Res, 2008. 4: p. 7.
8. Rotureau B and J. Van Den Abbeele.Through the dark continent: 
African trypanosome development in the tsetse fly., Front Cell Infect 
Microbiol., 2013. 3(53).
9. Vickerman, K.Polymorphism and mitochondrial activity in sleeping 
sickness trypanosomes, Nature, 1965. 208(12): p. 762-6.
10. Vickerman, K.The fine structure of Trypanosoma congolense in its 
bloodstream phase, J Protozool, 1969. 16(1): p. 54-69.
11. Gardiner, P.R. and A.J. Wilson.Trypanosoma (Duttonefla) vivax, 
Parasitol Today, 1987. 3(2): p. 49-52.
12. Nantulya, V.M., J.J. Doyle, and L. Jenni.Studies on Trypanosoma 
(nannomonas) congolense. I. On the morphological appearance of the 
parasite in the mouse, Acta Trop, 1978. 35(4): p. 329-37.
13. Shapiro, S.Z., J. Naessens, B. Liesegang, S.K. Moloo, and J. 
Magondu.Analysis by flow cytometry of DNA synthesis during the life 
cycle of African trypanosomes, Acta Trop, 1984. 41(4): p. 313-23.
14. Sherwin, T. and K. Gull.The cell division cycle of Trypanosoma brucei 
brucei: timing of event markers and cytoskeletal modulations, Philos 
Trans R Soc Lond B Biol Sci, 1989. 323(1218): p. 573-88.
15. Mony, B.M., P. MacGregor, A. Ivens, F. Rojas, A. Cowton, J. Young, D. 
10
Horn, and K. Matthews.Genome-wide dissection of the quorum 
sensing signalling pathway in Trypanosoma brucei, Nature, 2014. 
505(7485): p. 681-5.
16. Dean, S.D., R. Marchetti, K. Kirk, and K. Matthews.A surface 
transporter family conveys the trypanosome differentiation signal, 
Nature 2009. 459: p. 213-217.
17. Coustou, V., F. Guegan, N. Plazolles, and T. Baltz.Complete in vitro 
life cycle of Trypanosoma congolense: development of genetic tools, 
PLoS Negl Trop Dis, 2010. 4(3): p. e618.
18. Hirumi, H. and K. Hirumi.Continuous cultivation of Trypanosoma brucei 
blood stream forms in a medium containing a low concentration of 
serum protein without feeder cell layers, J Parasitol, 1989. 75(6): p. 
985-9.
19. MacGregor, P. and K.R. Matthews.Identification of the regulatory 
elements controlling the transmission stage-specific gene expression 
of PAD1 in Trypanosoma brucei, Nucleic Acids Res, 2012. 40(16): p. 
7705-17.
20. Laxman, S., A. Riechers, M. Sadilek, F. Schwede, and J.A. 
Beavo.Hydrolysis products of cAMP analogs cause transformation of 
Trypanosoma brucei from slender to stumpy-like forms, Proc Natl 
Acad Sci U S A, 2006. 103(50): p. 19194-9.
21. Bastin, P., Z. Bagherzadeh, K.R. Matthews, and K. Gull.A novel 
epitope tag system to study protein targeting and organelle biogenesis 
in Trypanosoma brucei, Mol Biochem Parasitol, 1996. 77(2): p. 235-9.
22. Eswarappa, S.M., S. Estrela, and S.P. Brown.Within-host dynamics of 
multi-species infections: facilitation, competition and virulence, PLoS 
One, 2012. 7(6): p. e38730.
23. Balmer, O., S.C. Stearns, A. Schotzau, and R. Brun.Intraspecific 
competition between co-infecting parasite strains enhances host 
survival in African trypanosomes, Ecology, 2009. 90(12): p. 3367-78.
24. Bruce, M.C., C.A. Donnelly, M.P. Alpers, M.R. Galinski, J.W. Barnwell, 
D. Walliker, and K.P. Day.Cross-species interactions between malaria 
parasites in humans, Science, 2000. 287(5454): p. 845-8.
25. Portugal, S., C. Carret, M. Recker, A.E. Armitage, L.A. Goncalves, S. 
Epiphanio, D. Sullivan, C. Roy, C.I. Newbold, H. Drakesmith, et al.Host-
mediated regulation of superinfection in malaria, Nat Med, 2011. 
17(6): p. 732-7.
26. MacGregor, P., B. Szoor, N.J. Savill, and K.R. 
Matthews.Trypanosomal immune evasion, chronicity and transmission: 
an elegant balancing act, Nat Rev Microbiol, 2012. 10(6): p. 431-8.
27. Diggle, S.P., A.S. Griffin, G.S. Campbell, and S.A. West.Cooperation 
and conflict in quorum-sensing bacterial populations, Nature, 2007. 
450(7168): p. 411-4.
28. Fevre, E.M., B.V. Wissmann, S.C. Welburn, and P. Lutumba.The 
burden of human African trypanosomiasis, PLoS Negl Trop Dis, 2008. 
2(12): p. e333.
29. MacLean, L., J.E. Chisi, M. Odiit, W.C. Gibson, V. Ferris, K. Picozzi, 
and J.M. Sternberg.Severity of human african trypanosomiasis in East 
11
Africa is associated with geographic location, parasite genotype, and 
host inflammatory cytokine response profile, Infect Immun, 2004. 
72(12): p. 7040-4.
30. MacLean, L.M., M. Odiit, J.E. Chisi, P.G. Kennedy, and J.M. 
Sternberg.Focus-specific clinical profiles in human African 
Trypanosomiasis caused by Trypanosoma brucei rhodesiense, PLoS 
Negl Trop Dis, 2010. 4(12): p. e906.
End Notes
Supplementary Information is linked to the online version of the paper at 
www.nature.com/naturemicrobiology
Correspondence and requests for materials should be addressed to Keith 
Matthews (keith.matthews@ed.ac.uk)
Acknowledgements
This work was supported by a Wellcome Trust Investigator award 
(103740/Z/14/Z) and Royal Society Wolfson Research merit award 
(WM140045) to KM and a BBSRC studentship to ES. The Centre for 
Immunity, Infection and Evolution is supported by a Strategic Award from the 
Wellcome Trust (095831). We thank Margo Chase-Topping for assistance 
with statistical analysis, Martin Waterfall for assistance with flow cytometry
and Jacqueline Matthews for comments on the manuscript.
Author Contributions
Conceived and supervised the study (KRM), devised the experiments (ES,
KRM), planned and carried out the experiments (ES, JY), collated, analysed
and interpreted the data (ES, KRM, AI), wrote the manuscript (KRM, ES).
Competing financial interests
The authors declare that they have no competing financial interests in 
relation to this work.
12
Figure legends
Figure 1 
T. congolense cell cycle analysis reveals a reduction in proliferating cells at 
the peak of parasitaemia.
a) Cell cycle analysis over the first 14 days of infection for six mice infected 
with T. congolense ILTat3000. The slope of the percentage of proliferating 
cells (2K1N – G2-phase cells, 2K2N – post-mitotic cells) and the 
parasitaemia showed significant deviation from zero (p=0.0003). 500 
parasites were scored per sample unless parasitaemias were very low, when 
200 cells were scored.
b) Phase contrast images of T. brucei slender (3 days post infection) and 
stumpy forms (6 days post infection) (top) and T. congolense ILTat3000 over 
7 days of infection. Cells were counterstained with DAPI to reveal the nucleus 
and kinetoplast. Scale bar= 10µm.
c) Forward and side scatter profiles of slender (3 days post infection, n=2) 
and stumpy form (6 days post infection, n=2) parasites highlighting 
morphological differences between the developmental forms.
d) Forward and side scatter profiles of T. congolense ILTat3000 during 
ascending parasitaemia (5 days post infection, n=2) or at the first peak of 
parasitaemia (7 days post infection, n=2). Inset images show the absence of 
morphological difference between each population. Scale bar= 10µm.
Figure 2
A T. congolense orthologue of a T. brucei QS response pathway component, 
TbHYP2, can restore stumpy formation in a T. brucei TbHYP2 null mutant in 
murine infections.
a) A T. brucei EATRO 1125 TbHyp2 null mutant was generated by sequential 
allelic replacement in the parental cell line T. brucei AnTat1.1 90:13. The 
TbHyp2 null mutant (T. brucei AnTat1.1 90:13 TbHYP2 dKO) was then 
transfected with a construct for the doxycycline-inducible ectopic expression 
of TcHYP2 (TcHYP2 OE in KO).
b) Growth of the T. brucei EATRO 1125 TbHyp2 null mutant cell line with 
doxycycline-inducible TcHYP2 expression (TcHyp2 OE in KO) in mice. 
Parasite population growth was limited in infections where TcHYP2 ectopic
expression was induced (+Dox, red lines, n=3) relative to uninduced controls 
(-Dox, blue lines, n=3). Parental T. brucei AnTat 1.1 90:13 (black line, n=1) 
and T. brucei EATRO 1125 TbHYP2 null mutant (navy line, n=1) cell lines 
were included as controls (further replicates are provided in Supplementary
Figure 4). Crosses indicate humane euthanasia when infections were 
anticipated to be lethal within 12 hours.
c) Expression of the stumpy marker PAD1 was higher when TcHYP2 was 
ectopically expressed in the T. brucei EATRO 1125 TbHyp2 null mutant than 
in the uninduced control. TY1-tagged TcHYP2 protein was detected with BB2 
antibody in +Dox samples but not in –Dox samples. Glucose-6-phosphate 
dehydrogenase, loading control.
13
d) Cells induced to express TcHYP2 (+Dox, n=3) had increased capacity to 
differentiate to procyclic forms relative to uninduced cells (-Dox, n=3) 
following treatment with cis-aconitate, as determined by EP procyclin 
expression at 4h and 24h after treatment (unpaired t test,     p<0.0001,   
p<0.01, two-sided). Bars represent mean ± SD). Parental T. brucei AnTat 1.1 
90:13 stumpy (green, n=1) and culture-derived slender (orange, n=2) cells,
as well as T. brucei EATRO 1125 TbHYP2 null mutant (navy, n=1) cells were 
included as controls. Culture-derived procyclic cells (purple, n=1) were used 
as a positive control for procyclin expression.
Figure 3
Treatment with T. brucei- or T. congolense- conditioned medium inhibits 
growth of pleomorphic T. brucei via QS-signalling.
a) A pleomorphic T. brucei cell line (EATRO 1125) with a CAT reporter under 
the control of the PAD1 3’UTR (T. brucei AnTat1.1 90:13 CAT-PAD) was 
used to report on stumpy formation in response to conditioned medium 
treatment. Growth of this cell line was inhibited by treatment with 75% T. 
brucei- (TbCM) or 75% T. congolense- (TcCM) conditioned medium relative 
to non-conditioned control media (TbN and TcN). Data points represent the 
mean ± SEM of n=3 flasks.
b) CAT concentration/cell was elevated after 1 or 2 days of treatment with 
TbCM or TcCM (unpaired t test, p<0.05,    p<0.001, two-sided). Bars 
represent mean ± SD of n=3 flasks. The effect of TcCM was reproducible in 
three (out of three) independent experiments (one representative experiment 
is shown). The negative controls expressed an elevated CAT 
concentration/cell on day 3 because cultures were maintained without 
passage such that cell growth caused accumulation of the QS signal.
c) A CAT PAD 3’UTR reporter construct was transfected into a pleomorphic 
cell line (T. brucei EATRO 1125 AnTat1.1 90:13) with the capacity for 
doxycycline-inducible knock down of the QS-signalling component TbHYP2
(T. brucei AnTat1.1 90:13 CAT-PAD TbHYP2 RNAi). When this cell line was 
treated with TbCM, the increase in CAT concentration/cell was muted in cells 
where TbHYP2 RNAi had been induced relative to uninduced cells. Bars 
represent the mean ± SEM of n=3 flasks.
d) When the same cell line was treated with TcCM, the increase in CAT 
concentration/cell was diminished in cells where TbHYP2 RNAi had been 
induced relative to uninduced cells. Comparisons between categories were 
made using two-way ANOVA followed by Tukey’s multiple comparison test (
p<0.05,   p<0.01,    p<0.001,     p<0.0001). Bars represent the mean ± SEM 
of n=3 flasks. The effect of TcCM and TbCM on this cell line was 
reproducible in two (out of two) independent experiments (one representative 
experiment is shown).
Figure 4
Pleomorphic T. brucei introduced into an established T. congolense infection 
differentiate prematurely to stumpy forms in an effect mediated by QS-
signalling.
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a) Pleomorphic T. brucei EATRO 1125 encoding Ty1 epitope-tagged PFRA 
(T. brucei AnTat1.1 90:13 PFR-Ty1) were used to identify T. brucei in mixed 
infections by flagellar staining (green). Note that T. congolense cells show 
non-specific intracellular staining with the BB2 antibody that detects the Ty1 
epitope. A PAD1-positive T. brucei stumpy cell (arrowhead) is shown 
surrounded by T. congolense cells on day 8 of the co-infection experiment. 
PAD1-red. DAPI-purple. Scale bar, 10µm.
b) The proportion of each parasite species was determined by scoring >2000 
cells in the co-infections as PFR-Ty1 positive or negative, and applied to the 
total parasitaemia to calculate the effective parasitaemia of each species in 
the co-infections on days 6, 7 and 8. The effective T. brucei parasitaemia in 
the co-infections (purple, n=3) remained lower than in the control ‘T. brucei
only’ infections (blue, n=3). Green; T. congolense in the co-infections (n=3).
Red; ‘T. congolense only’ infections (n=3).
c) PAD1-positive T. brucei on day 8 of the experiment (>500 cells scored, 
n=3 for each condition tested). Despite lower T. brucei parasitaemia in the 
superinfections there was a higher percentage of PAD1-positive cells 
compared with the single species T. brucei infections (unpaired t test,   
p<0.01, two-sided). Error bars represent mean ± SD.
d) A cell line with a Ty1 epitope tagged PFRA protein and the capacity for 
doxycycline-inducible TbHYP2 RNAi was generated. Effective RNAi targeting 
TbHYP2 was confirmed by Northern blot using RNA collected after 48 hours 
of culture ± doxycycline. Ethidium bromide stained rRNA acts a loading 
control. 
e) The proportion of parasites of each species was calculated as in the panel 
b (n=3 for each condition tested). The effective T. brucei parasitaemia was 
lower in superinfections than in ‘T. brucei only’ infections, whether or not
TbHYP2 RNAi was induced. The effective T. brucei parasitaemia was higher 
in co-infections where TbHyp2 RNAi was induced (+Dox) than those without 
induction (-Dox), though the difference was not significant.
f) PAD1-positive T. brucei on day 8 of the experiment (>500 cells scored, n=3 
for each condition tested). There were significantly more PAD1-positive T. 
brucei cells in the co-infections where TbHyp2 RNAi was not induced (30-
45%) than in co-infections where TbHYP2 RNAi was induced (1-3%) (    
p<0.0001, One-way ANOVA with Tukey’s multiple comparisons test). Error 
bars represent mean ± SD.
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Methods
Animal experiments Animals were allocated at random into treatment 
groups from a group of female, age matched adult MF1 mice, at least 10 
weeks old. No blinding was done.
T. congolense IL3000 infections
T. congolense parasites of the IL3000 strain were used both for infections 
and in vitro experiments. This strain was derived from the ILC-49 strain that 
was isolated from a cow in the Trans Mara, Kenya
31
. The T. congolense
IL3000 parasites used for in vivo experiments were provided by Dr Annette 
MacLeod (University of Glasgow) in a blood straw. The T. congolense IL3000 
parasites used for in vitro experiments were supplied as culture-adapted 
bloodstream forms by Dr Liam Morrison (Roslin Institute, Edinburgh), who 
had received them from Professor Théo Baltz (University of Bordeaux). Six 
female MF1 mice were inoculated intraperitoneally with T. congolense
ILTat3000. Parasitaemia was monitored daily from day 3 post-infection. 
Parasitaemia was estimated from a wet blood smear using the Herbert and 
Lumsden rapid matching method
32
. Air-dried blood smears were fixed in ice-
cold methanol and stored at -20°C prior to cell cycle analysis.
T. brucei null mutant infections
Three female cyclophosphamide-treated MF1 mice were inoculated 
intraperitoneally with the TbHyp2 null mutant cell line. In parallel two mice 
were inoculated with the parental AnTat1.1 90:13 cell line. Parasitaemia was 
monitored daily from day 3 post-infection. Parasitaemia was estimated from a 
wet blood smear using the Herbert and Lumsden rapid matching method
32
. 
Infections were monitored until parasites differentiated to stumpy forms or 
were terminated if the uncontrolled ascending parasitaemia was predicted to 
become lethal within the next 12 hours. At the end of the experiment 
parasites were purified from whole blood by passage through a DE52 column 
(Whatman
®
anion exchange cellulose, Z742600) at pH 7.8.
Infections to test functional complementation
Six female cyclophosphamide-treated MF1 mice were inoculated 
intraperitoneally with the TcHyp2 overexpression TbHyp2 null mutant cell 
line. One group (n=3) was provided with doxycycline (200μg/ml in 5% 
sucrose) in their drinking water from the time of inoculation to induce TcHyp2 
overexpression. The other group (n=3) received 5% sucrose only. In parallel 
one mouse was infected with AnTat1.1 90:13 and one mouse with the 
TbHYP2 null mutant. Parasitaemia was monitored daily from day 3 post-
infection. Parasitaemia was estimated from a wet blood smear using the 
Herbert and Lumsden rapid matching method
32
. Infections were monitored 
until parasites differentiated to stumpy forms or were terminated if the 
uncontrolled ascending parasitaemia was predicted to become lethal within 
the next 12 hours. At the end of the experiment parasites were purified from 
16
whole blood by passage through a DE52 column (Whatman
®
anion exchange 
cellulose, Z742600) at pH 7.8.
Cell cycle analysis
Methanol-fixed blood smears were rehydrated in PBS for 5 min. Slides were 
stained with 30μl of DAPI (10μg/ml in PBS) for 2 min in a humidity chamber 
and were then washed for 5 min in PBS. Slides were then mounted with 40μl 
Mowiol containing 2.5% DABCO (1, 4-diazabicyclo[2.2.2]octane). Nucleus 
and kinetoplast configurations were recorded by manual cell counting. 500 
cells were counted per sample and per timepoint except where there was 
very low parasitaemia, where 200 cells were counted.
Generation of a TbHYP2 null mutant with inducible TcHYP2 
overexpression
pEnT6B-Y and pEnT6P-Y vectors
33
 were used to generate the TbHYP2 null 
mutant by sequential allelic replacement. Primers were designed to amplify 
regions of the 5’UTR and 3’UTR of TbHYP2 in order to replace the 
endogenous gene with a cassette containing either a puromycin or blasticidin
resistance marker. Constructs were used to transfect the pleomorphic 
AnTat1.1 90:13 cell line, and successful generation of a null mutant was 
confirmed by Southern blotting. 
Primers (F primer: GGGTTTACTAGTATGGCCTCAGAGTCAGCG, R primer: 
GGGTTTGGATCCCTACCCCCGTCCCTGTCC) were designed to amplify 
TcHyp2 (TcIL3000.0.19510) with appropriate terminal restriction sites for 
insertion into the pDex577-Y vector for tetracycline-inducible overexpression 
with an N-terminal TY epitope tag
21
. The overexpression construct was used 
to transfect the TbHYP2 null mutant and inducible overexpression was 
confirmed by Western blotting using an anti-TY antibody (BB2
21
).
Southern blotting
A gene probe was produced to detect the presence of the TbHYP2 gene and 
a 5’UTR probe was designed to detect the correct integration of both 
constructs. PCR reactions with Q5 high fidelity DNA polymerase (NEB, 
M0491S) were used to generate material for the 5’UTR probe (F primer: 
ACTAGTACATGCTGGTCGTCAGTATT, R primer: 
GGATCCATCAGTGCACGTATTCTACCA) and gene probe (F primer: 
GGGTTTACTAGTATGGCATCGGAGGCAGCG, R primer: 
GGGTTTGGATCCTTATTCGCCCCTAACTGC). Purified DNA was then used 
to generate DIG-labelled probes with the DIG High Prime labelling and 
detection starter kit II (Roche, 11585614910). 1μg of genomic DNA extracted 
from parental AnTat1.1 90:13 cells, cells with suspected single allelic 
replacement of TbHyp2 and cells with suspected double allelic replacement 
of TbHyp2 was digested overnight at 37°C by PstI (Promega, R6111). 
Digested DNA was divided between two lanes (one for each probe) and 
resolved on an agarose gel for 3h at 100V. The gel was then soaked 
successively in depurination solution (0.25M HCl), denaturation solution 
(1.5M NaCl/0.5M NaOH) and neutralisation solution (1M Tris/1.5M 
NaCl/pH7.4) prior to transfer of the DNA to a nylon membrane overnight. The 
membrane was then UV cross-linked. Hybridisation was carried out overnight 
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at 42°C with the DIG-labelled DNA probe in DIG Easy Hyb Buffer (Roche, 
11603558001). The membrane was washed twice for 5 min in 
2xSSC/0.1%SDS at RT, and then twice for 15 min on 0.5xSSC/0.1%SDS at 
68°C. The membrane was blocked for 1h with Maleic acid buffer containing 
1% DIG block, before addition of 2μl anti-DIG (Roche, 11093274910) and 
incubation for 30 min. Final detection used the chemiluminescent substrate 
CDP-Star (Roche, 11685627001) diluted 1:100 in detection buffer (100mM 
Tris HCl 100mM NaCl pH9.5).
Western blotting
Protein samples were resolved on SDS-PAGE gels and blotted onto 
nitrocellulose membrane. Primary antibody dilutions were prepared in 5% 
milk and the membrane was incubated overnight. αBB2 antibody
21
 was used 
at 1:20 to detect the TY-tagged TcHyp2, αPAD1 antibody
16
 was used at 
1:1000. αG6PDH (glucose-6-phosphate dehydrogenase, kind gift of 
Professor Paul Michels, University of Edinburgh) was used for loading 
controls at 1:10,000, and αEF1 (elongation factor 1-alpha, Merck Millipore 05-
235) was used for loading controls at 1:7000. Secondary antibodies were 
diluted in 50% PBS and 50% Li-cor blocking buffer. Both anti-mouse (IRDye®
680 goat anti-mouse, Li-cor) and anti-rabbit (goat anti-rabbit IgG (H+L) 
Dylight 800, Thermoscientific) secondary antibodies were diluted 1:7500. 
Immunofluorescence was detected on the Li-cor Odyssey imaging system. 
In vitro differentiation to procyclic forms
Parasites were resuspended at 2x10
6
/ml in SDM79 medium (GIBCO by Life 
technologies) containing 6mM cis-aconitate (Sigma, A3412) and were 
incubated at 27°C. Samples were collected for flow cytometry at 0h, 4h and 
24h.
Flow cytometry
2-5x10
6
 cells were washed twice in PBS prior to fixing in 500μl 2% 
formaldehyde/0.05% glutaraldehyde >1h at 4°C. Cells were then washed 3x 
in PBS and resuspended in 2%BSA:PBS for 30 min. Cells were then 
resuspended in primary antibody diluted in 2%BSA:PBS (αPAD1 was diluted 
1:200, αEP procyclin (Cedar Lane laboratories) was diluted 1:500) and were 
incubated overnight at 4°C. The cells were washed twice in PBS and were 
resuspended in secondary antibody diluted in 2%BSA:PBS (α-rabbit CY5 and 
α-mouse FITC were each diluted 1:1000). The cells were washed twice in 
PBS and were resuspended in 500μl PBS containing 0.02μg/ml DAPI. 
Samples were then processed on an LSRII flow cytometer (BD Biosciences). 
Positive controls and secondary antibody only controls were included. 
Analysis was performed using FlowJo software (Tree Star).
Conditioned medium generation
For generation of conditioned medium, cultures of T. brucei AnTat1.1 90:13 
were established at 1x10
5
cells/ml in HMI-9
34
 and were incubated for 2 days at 
37°C (and 5%CO2). Conditioned medium was harvested when cells had 
reached a density of 2-3x10
6
/ml, by pelleting the cells and passing the 
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supernatant through a 0.22μm filter. Filtered supernatant was stored at 4°C. 
Cultures of T. congolense for generating conditioned medium were in most 
cases established at 1x10
5
 cells/ml in TcBSF3
17
 and were incubated for 3 
days at 34°C (and 5%CO2). Conditioned medium was collected at a range of 
densities from 5x10
6
 cells/ml to 1x10
7
 cells/ml, and prepared as for T.  brucei 
conditioned medium by filtering of conditioned supernatant through a 0.22μm 
filter. Conditioned medium was stored for a maximum of 5 days at 4°C before 
use. Alongside flasks for conditioned medium generation, flasks containing 
either HMI-9 or TcBSF3 without parasites were prepared, and this control 
medium was treated in the same way as the conditioned medium and used as 
a negative control in all conditioned medium experiments.
CAT reporter experiments
A pleomorphic cell line with a CAT reporter under the control of the PAD1 
3’UTR was used to report on stumpy formation
19
. Additionally, a pleomorphic 
cell line with inducible TbHYP2 RNAi
15
 was transfected with the CAT PAD1 
3’UTR construct or a control construct with CAT reporter expression 
controlled by the 3’UTR of the constitutively expressed aldolase gene
19
. 
The CAT reporter T. brucei cells were washed once with HMI-9 and 
resuspended at a density of 2x10
5
 cells/ml in a mixture of 75% conditioned 
medium or control medium and 25% HMI-9. Cultures were incubated for 3 
days at 37°C (and 5%CO2) without passage. Each day cell number was 
estimated using a Beckman Coulter Z2 Coulter Particle count and size 
analyser (or haemocytometer if there were a number of dead cells), and CAT 
ELISA samples were collected. For experiments involving Hyp2 RNAi, 
induction of the RNAi with doxycycline was initiated one day before the 
addition of conditioned medium, and was maintained throughout the 
experiment. CAT ELISA samples were prepared by collecting 5ml of culture, 
washing cells 3x with PBS, and resuspending in 1ml CAT lysis buffer (Roche) 
for 25 min at RT. The lysis reaction was centrifuged to pellet debris and the 
supernatant was snap frozen in liquid nitrogen and stored at -80°C. 
Samples were analysed by CAT ELISA (Roche, 11363727001) to determine 
their CAT concentration according to the manufacturer’s instructions. Each 
sample was loaded into two wells of a 96 well plate. The CAT concentration 
of the samples was estimated by comparing the absorbance at 405nm to that 
of a CAT standard curve (provided by the manufacturer). The standard curve 
included a range of CAT concentrations of 0.0625ng/ml CAT to 2ng/ml CAT, 
as well as a blank of 0ng/ml. Absorbance was measured using a BioTek
ELx808 Absorbance Microplate reader with Gen5 data analysis software 
(BioTek). Reads of duplicate wells at 405nm were averaged and converted to 
CAT concentrations using the standard curve. CAT concentration/ cell was 
calculated using the number of cells in each 5ml sample collected during the 
experiment. 
Superinfection experiment
Six female MF1 mice were inoculated intraperitoneally with T. 
congolense ILTat3000 on day 0, each mouse received approximately 
2.4x10
6
cells. On day 4, three T. congolense-infected and three previously 
uninfected mice were inoculated intraperitoneally with T. brucei AnTat1.1 
19
90:13 with a TY-tagged PFR, each mouse received approximately 1.2x10
5
cells. Stocks used for infection were mixed prior to division between mice to 
ensure that single species infections and co-infections were initiated with the 
same T. brucei inoculum.
Parasitaemia was monitored daily from day 4 post-infection. Total 
parasitaemia was estimated from a wet blood smear using the Herbert and 
Lumsden rapid matching method
32
. 10μl of blood was collected on each day 
of infection, and cells were washed in 200μl cold PSG and resuspended in 
125μl cold PBS, and then 125μl 8% paraformaldehyde in PBS was added. 
Cells were fixed on ice for 10 min and then resuspended in 130μl 0.1M 
glycine in PBS, and kept at 4°C overnight. Samples were then resuspended
in PBS and used for immunofluorescence. The proportion of the co-infection 
parasitaemia contributed by each species was estimated by counting the 
number of PFR-TY1 positive cells (>2000 cells scored). At the end of the 
experiment parasites were purified from whole blood by passage through a 
DE52 column (Whatman
®
anion exchange cellulose, Z742600) at pH 7.8. 
Purified parasites were paraformaldehyde fixed for immunofluorescence and 
these samples were used to determine the proportion of T. brucei that were 
PAD1 positive in the infections (>500 cells scored), as well as the KN 
configuration of these cells.
Superinfection experiment with TbHYP2 RNAi induction
Six female MF1 mice were inoculated intraperitoneally with T. congolense
ILTat3000 on day 0, each mouse received approximately 2.4x10
6
cells. On 
day 4, all six T. congolense-infected and six previously uninfected mice were 
inoculated intraperitoneally with a T. brucei EATRO1125 AnTat1.1 90:13 cell 
line with a TY-tagged PFR and doxycycline-inducible RNAi targeting 
TbHYP2, each mouse received approximately 1.2x10
5
 cells. Stocks used for 
infection were mixed prior to division between mice to ensure that all 
infections were initiated with the same T. brucei inoculum.
On day 1 of the experiment doxycycline (200μg/ml in 5% sucrose) was 
provided in the drinking water of three of the T. congolense infected mice and 
three of the uninfected mice, the remaining mice received 5% sucrose only. 
Parasitaemia was monitored and samples were collected as for the initial 
superinfection experiment.
Immunofluorescence 
Paraformaldehyde fixed cells were adhered to Polysine® slides (VWR, 631-
0107). 20μl 0.1% triton in PBS was applied to each well for 2 minutes, this 
was then aspirated and wells were washed with a large drop of PBS. Wells 
were blocked with 2% BSA:PBS for 45 minutes at 37°C in a humidity 
chamber, before application of 20μl primary antibody. Wells were incubated 
with primary antibody (diluted in 2% BSA:PBS, αPAD1 1:1000, BB2 1:20) for 
45 minutes at 37°C in a humidity chamber. Positive control wells and 
secondary antibody only wells were included for each experiment. Wells were 
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each washed 5 times by repeatedly applying and aspirating 1x PBS. Wells 
were incubated with 20μl secondary antibody (diluted in 2% BSA:PBS, α-
rabbit Alexa fluor 488 1:500, α-mouse Alexa fluor 568 1:500) for 45 minutes 
at 37°C in a humidity chamber. 20μl of a DAPI working dilution (10μg/ml in 
PBS) was then applied to each well for 1 minute, followed by 5 washes with 
PBS. Slides were mounted with a cover slip by application of Mowiol
containing 2.5% DABCO. Slides were analysed on a Zeiss Axioskop 2 plus or 
Zeiss Axio Imager Z2, and QCapture software was used for image capture.
Images of BB2, PAD1 and DAPI staining were overlaid in ImageJ 64
35
 and 
cell counts were performed using the Cell Counter Plugin.
Bioinformatic analysis
The BLASTP tool on TritrypDB
36
 was used for identification of orthologues.
Statistical analysis
Most statistical analyses were carried out in GraphPad Prism version 6 
(GraphPad Software, La Jolla, California, USA, www.graphpad.com). A 
General Linear Model was used to analyse T. congolense parasitaemias for 
cell cycle arrest using Minitab®. This model tested the significance of the 
effect of parasitaemia on % 2K1N, 2K2N cells and incorporated mouse as a 
random factor, which was not significant (p=0.55) In all analyses a p-value 
<0.05 was considered significant. Where the analyses used work on the 
assumption of a normal distribution, the distribution of the data was assessed
before performing the analyses, and if required the data was transformed 
prior to testing.
Animal studies and group sizes
Animal experiments were carried out according to the UK Animals (Scientific) 
Procedures act under a licence (PPL60/4373) issued by the UK Home Office 
and approved by the University of Edinburgh Local ethical committee.
For the analysis of phenotypes 3- 5  animals per treatment were routinely 
used for analysis. Our previous analyses (e.g. Mony, B.M., et al., Genome-
wide dissection of the quorum sensing signalling pathway in Trypanosoma 
brucei. Nature, 2014. 505(7485): p. 681-5)
15
 indicate that this sample size 
is sufficient to detect differences between cell lines and treatment groups (for 
example where gene silencing is activated by provision of doxycycline). 
Using that data as an exemplar, we tested 5 genes for effects with and 
without doxycycline mediated gene-silencing in vivo. Using cell cycle status 
as the measured parameter,  the effect size ranged from 0.637 to 1.804. 
Those values were then used to calculate the power for different samples 
sizes. This showed that a sample size of 3-5 per group (+ or - DOX) , or total 
of 6 to 10 allowed us to achieve 80% power for all test genes except one. In 
our current manuscript, the visual analytical assays applied (manual scoring 
by microscope) to the different treatments and groups (cell cycle scoring, 
analysis of PAD1 staining, scoring of flagellar labelling for parasite species, 
morphological analysis) required analyses to be limited to 3 animals per 
21
group. Data were examined before analysis to ensure normality and that no 
transformations were required. P values of less than 0.05 were considered 
statistically significant. 
Data Availability
The datasets generated during and/or analysed during the current study are
available either within the manuscript or from the corresponding author on
reasonable request. 
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Interspecies quorum-sensing in co-infections can manipulate 
trypanosome transmission potential
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Supplementary
data
Protein phosphatase Tb927.4.3620 TcIL3000.11.8600 58 78
Protein phosphatase Tb927.4.3640 TcIL3000.11.8600 57 78
Protein phosphatase Tb927.4.3630 TcIL3000.11.8600 57 78
Protein Kinase Tb927.10.5940 TcIL3000.10.4970 89 95
Protein Kinase Tb927.10.5930 TcIL3000.10.4970 90 95
Protein Kinase Tb927.10.5950 TcIL3000.10.4970 88 93
Protein Kinase Tb927.2.2720 TcIL3000.0.44450                   39 54
Protein Kinase Tb927.10.15020 TcIL3000.10.12870 49 63
Hypothetical Protein (Hyp 1)  Tb927.11.6600 TcIL3000.11.7200                  46 62
Hypothetical Protein (Hyp 2) Tb927.9.4080 TcIL3000.0.19510                   45 58
RNA-binding protein Tb927.10.12100 TcIL3000.10.10320 73 81
Adenylosuccinate synthetase (Purine pathway) Tb927.11.3650 TcIL3000.11.3610               86 93
Adenylosuccinate Lyase (Purine pathway) Tb927.9.7550 TcIL3000.0.18960              82 91
GMP synthase Tb927.7.2100 TcIL3000.0.55050 77 87
ubiquitin activating enzyme, putative Tb927.2.4020 TcIL3000.2.550 54 70
serine/threonine protein kinase, putative Tb927.3.4560 TcIL3000.10.4460                 51 69
hypothetical protein, conserved (Hyp 3) Tb927.4.670 TcIL3000.4.290 59 74
hypothetical protein (Hyp 4) Tb927.4.3650 TcIL3000.10.810                   25 44
adenosine kinase, putative Tb927.6.2300 TcIL3000.6.1860 72 86
adenosine kinase, putative Tb927.6.2360 TcIL3000.6.1860 73 86
kinetoplastid-specific dual specificity phosphatase, putative Tb927.7.7160 TcIL3000.0.52520                    41 52
hypothetical protein, conserved (Hyp 6) Tb927.9.13530 TcIL3000.9.5770 48 66
inosine-5'-monophosphate dehydrogenase Tb927.10.16120 TcIL3000.5.1940 37 55
phosphatase and tensin homologue, putative Tb927.11.290 TcIL3000.11.210                       67 80
protein kinase A regulatory subunit Tb927.11.4610 TcIL3000.0.15340 76 88
transcription silencer (ISWI) Tb927.2.1810 TcIL3000_2_50 62 76
Phosphoglycerate mutase Tb927.5.3580 TcIL3000_0_40660 79 90
Hypothetical protein (Hyp 5) Tb927.8.2860 TcIL3000_0_41460 40 56
Hypothetical protein, conserved (Hyp 8) Tb927.11.300 TcIL3000.11.220 53 65
DNA repair protein, putative (Hyp 9) Tb927.11.750 TcIL3000_0_15260 72 85
Product: protein phosphatase 2C, putative Tb927.11.760 TcIL3000_0_15250 83 90
Hypothetical protein, conserved (Hyp 10) Tb927.11.1640 TcIL3000.11.1420 42 60
Hypothetical protein, conserved (Hyp 11) Tb927.11.2250 TcIL3000.11.2000                    45 67
Hypothetical protein, conserved (Hyp 13) Tb927.11.11470 TcIL3000_0_22050 66 75
Trichohyalin, putative Tb927.11.11480 TcIL3000_0_28560                63 80
Identity/Similarity
>75%
50-75%
25-50%
<25%
Reciprocal BLAST?Predicted gene function T. brucei  ID T. congolense  ID % identity % similarity
Supplementary Table 1
T. congolense encodes predicted orthologues of components of the T. brucei stumpy formation
pathway.
T. brucei QS-signalling molecules were analysed by BLASTP at TritrypDB
(http://tritrypdb.org/tritrypdb/). T. congolense was selected as the target organism and default
parameters were used. The top T. congolense hit is reported alongside the respective % identity
and % similarity of the amino acid sequences. A green dot in the final column indicates that the
top T. congolense hit returned the original T. brucei protein when reciprocal BLAST was
performed.
Hypothetical Protein 2 (Tb927.9.4080)
Function or annotation Hypothetical, conserved (HYP2)
Annotation in TritrypDB
Component of the stumpy induction factor (SIF) signalling pathway (IMP, PMID:24336212)1
Fragments of this protein increase translation or mRNA stability when tethered to a reporter 
mRNA (PMID:24945722)2
Interacts with MKT1 (PMID:24470144; IPI)3
RITSeq Phenotype4 Loss-of-fitness in differentiation from bloodstream to procyclic forms
SIF resistance1 RNAi targeting HYP2 results in resistance to SIF and therefore reduced stumpy formation in vivo
Predicted domains5 Prokaryotic dksA C4-type zinc finger signature and profile (InterPro IPR000962, PROSITE 
PS51128); P-loop containing nucleoside triphosphate hydrolases (InterPro IPR027417, 
Superfamily SSF52540, Gene3D G3DSA:3.40.50.300); DNA ligase/ mRNA capping enzyme 
(Superfamily SSF56091, Gene3D G3DSA:3.30.470.30)
Eukaryotic linear motifs6 Phosphorylation sites favoured by PKA-type AGC kinase (MOD_PKA_1 and _2), 
NEK2(MOD_NEK2_1 and _2) or CDK (MOD_CDK_1); PP1 catalytic subunit interaction motif 
(DOC_PP1_RVXF_1), docking motif that assists in regulating specific interactions with the MAPK 
cascade (DOC_MAPK_1), motif for eIF4E binding (LIG_eIF4E_1), Retinoblastoma protein 
interaction domain (LIG_Rb_LxCxE_1), BRCA1 interaction domain (LIG_BRCT_BRCA1_1), 
potential interaction with TNFR signalling pathway (LIG_TRAF2_1)
mRNA expression profile7 Slender – 62.6,  Intermediate – 65.0,  Stumpy - 59.6
Protein expression 
PCF/BSF8
1.1406
Phospho site9 S258
Much of this information is available in the Supplementary tables of Mony et al Nature 2014 505 (7485): p. 681-5
Source data 
1. Mony et al Nature 2014 505 (7485): p. 681-5
2. Erben et al PLoS Pathogens 2014 10: e1004178
3. Singh et al Nucleic acids research 2014 42: 4652-4668
4. Alsford et al Genome Research 2011 21: 915-924
5. Mitchell et al Nucleic acids Research 2015 43: D213-D221
6. Dinkel et al  Nucleic acids Research 2012 40: D242-251
7. Capewell et al PLoS One 2013 8 (6): e67069
8. Urbaniak et al PLoS One 2012 7 (5): e36619
9. Urbaniak et al J. Proteome Res. 2013 12 (5): pp 2233-2244
Supplementary Table 2
Characteristics of TbHYP2 based on its sequence, motifs, expression and functional information
available in the sources indicated.
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Supplementary Figure 1
Parasitaemia and cell cycle analysis for six T. congolense infections from days 3-14 post-infection.
For each infection a black line represents the parasitaemia, and blue bars represent the percentage of
proliferating cells (2K1N – G2-phase cells, 2K2N – post-mitotic cells). The percentage of proliferating cells
was calculated by analysing the kinetoplast and nuclear configuration of 500 cells (except for bars marked with
an asterisk for which 200 cells were analysed due to the low parasitaemia at these timepoints). When
parasitaemia exceeded approximately 8x107/ml a reduction in proliferating cells was observed.
Supplementary Figure 2
Characteristics of TbHYP2 showing the location of domains detected within the predicted
protein
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Supplementary Figure 3
Generation of a TbHYP2 (Tb927.9.4080) null mutant in a T. brucei AnTat 1.1 90.13 background.
a) Generation of TbHYP2 null mutants by sequential allelic replacement was confirmed by the
restriction digest of genomic DNA from two clonal cell lines with PstI followed by Southern blotting.
The use of probes targeted to either the 5’UTR or coding region of TbHyp2 revealed a characteristic
digest pattern that matched expectation confirming successful generation of two TbHYP2 null mutants
(C and D). TbHYP2 null mutant clone C was selected for further experimentation.
b) Schematic representation of expected banding patterns for the wild-type (WT) allele, the first allelic
replacement (sKO) or the second allelic replacement (dKO). Predicted band sizes obtained with the
5’UTR probe are represented by orange lines, those expected with the gene probe are represented by
blue lines. The total region detectable by the gene probe is represented by a thick green line. The total
region detectable by the 5’UTR probe is represented by a thick purple line.
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Supplementary Figure 4
Infections with a TbHYP2 null mutant reach high parasitaemia without evidence of growth control or
differentiation to stumpy forms.
a) Infectio s with the TbHYP null m tant (n=3) were monitored alongside infections with the parental
T bruc i nTat 1.1 90.13 line (n=2). Infections were terminated when ascending parasitaemias were
predicted to become lethal within 12h (crosses).
b) TbHYP2 null mutant cells did not express the stumpy marker PAD1 despite high parasitaemia as
visualised by western blot. EF1 was used as a loading control.
c) TbHYP2 null mutant cells showed reduced capacity to differentiate to procyclic forms following
induction with 6mM cis-aconitate, as determined by EP procyclin expression at 4h and 24h after
induction. Additionally, TbHYP2 null mutant cells showed reduced proliferation after 24h of induction
with cis-aconitate, compared to both slender (3 days post infection) and stumpy (6 days post infection)
control parasites. The EP procyclin expression and cell cycle data were obtained by flow cytometry.
T. congolense
0 1 2 3 4
105
106
107
Pa
ra
si
te
s/
m
l
Day
75% T.con CM + 25% HMI-9
75% TcBSF3 negative control medium + 25% HMI-9
50% T.con CM + 50% HMI-9
50% TcBSF3 negative control medium + 50% HMI-9
AnTat 1.1 90.13
0 1 2 3
105
106
107
Day
Pa
ra
si
te
s/
m
l
75% T.con CM + 25% HMI-9
75% TcBSF3 negative control medium + 25% HMI-9
50% T.con CM + 50% HMI-9
50% TcBSF3 negative control medium + 50% HMI-9
WT 427
0 1 2 3 4
105
106
107
Pa
ra
si
te
s/
m
l
Day
75% T.con CM + 25% HMI-9
75% TcBSF3 negative control medium + 25% HMI-9
50% T.con CM + 50% HMI-9
50% TcBSF3 negative control medium + 50% HMI-9
a cb
d e
f g
Supplementary Figure 5
a-c) The effect of T. congolense conditioned medium on T. brucei pleomorphic and monomorphic cell
lines, and T. congolense itself.
d-g) The effect of T. brucei conditioned medium and 8-pCPTcAMP on T. congolense and pleomorphic T.
brucei.
a) The effect of T. congolense conditioned medium on T. congolense ILTat3000.
b) The effect of T. congolense conditioned medium on pleomorphic T. brucei EATRO 1125 AnTat 1.1
90.13.
c) The effect of T. congolense conditioned medium on monomorphic Lister 427 T. brucei.
d) The effect of 75% T. brucei conditioned medium on T. congolense ILTat3000.
e) The effect of 75% T. brucei conditioned medium on T. brucei EATRO 1125 AnTat 1.1 90.13.
f) The response of T. congolense ILTat3000 to the cell permeable QS-signal mimic 8-pCPTcAMP.
g) The response of T. brucei EATRO 1125 AnTat 1.1 90.13 to the cell permeable QS-signal mimic 8-
pCPTcAMP.
Each data point represents the mean of triplicate wells; errors bars represent SEM, and are sometimes
obscured by the data point due to the high reproducibility of the assays.
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Supplementary Figure 6
Cell cycle status of T. brucei following treatment with T. brucei or T. congolense conditioned medium
with (+Dox) or without (-Dox) induction of RNAi targeting TbHyp2
The pleomorphic cell line T. brucei AnTat 90:13 CAT-PAD TbHYP2 RNAi was treated with TbCM or
TcCM and cells collected on days 1-3 of the experiment were scored for their kinetoplast and nuclear
configuration. Each bar represents the mean and standard deviation of triplicate flasks (250 cells counted
for each replicate). There was a reduction in the proportion of proliferating (2K1N, 2K2N) cells
following treatment with TbCM or TcCM when RNAi was not induced. The reduction in proliferating
cells was muted when TbHYP2 RNAi had been induced relative to uninduced cells. Comparisons
between categories were made using two-way ANOVA followed by Tukey’s multiple comparison test
(★ p<0.05, ★★ p<0.01, ★★★ p<0.001, ★★★★ p<0.0001). The effect of TcCM and TbCM on
this cell line was reproducible in two independent experiments (one representative experiment is
shown).
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Supplementary Figure 7
The effect of T. brucei conditioned medium and 8-pCPT-cAMP on a pleomorphic reporter line with
inducible TbHYP2 RNAi.
A pleomorphic T. brucei cell line (EATRO 1125; AnTat 1.1 90.13) capable of doxycycline inducible
knock down of TbHYP2 was transfected with either of two constructs. One construct encoded a CAT
reporter with expression under the control of an aldolase 3’UTR. When the cell line with this control
construct was treated with conditioned medium or the QS-signal mimic 8-pCPT-cAMP there was no
effect on CAT concentration/cell related to RNAi against TbHYP2. The second construct encoded a
CAT reporter with expression under the control of the PAD1 3’UTR. When the cell line with the CAT
PAD construct was treated with conditioned medium (AnTat CM) or 8-pCPT-cAMP the CAT
concentration/cell increased relative to the negative control (75% HMI-9). However, when TbHYP2
RNAi was induced (+Dox) the CAT concentration/cell did not increase with conditioned medium
treatment. For each condition tested n=1.
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Supplementary Figure 8
Cell cycle status of T. brucei in co-infection with T. congolense or in a single species infection.
T. brucei cells collected on day 8 of the experiment were scored for their kinetoplast and nuclear
configuration (>500 cells scored, n=3 for each condition tested). Error bars represent mean ±
SD. The lower T. brucei parasitaemia in the superinfections was associated with a significantly
higher proportion of 1K1N cells compared to that observed in the single species T. brucei
infections (unpaired t test,★ p<0.05, two-sided).
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Supplementary Figure 9
Representative images of day 8 superinfection samples with (+Dox) or without (-Dox) induction of
RNAi targeting TbHyp2.
An example of PAD1-positive intermediate/stumpy T. brucei cells accompanied by T. congolense
on day 8 of the co-infection experiment when TbHyp2 RNAi has not been induced (-Dox), and an
example of a PAD1-negative, slender, T. brucei cell accompanied by T. congolense when
TbHYP2 RNAi has been induced (+Dox). PFR-Ty1 (red), PAD1 (green), DAPI (white). Note that
T. congolense cells show non-specific intracellular staining with the BB2 antibody that detects the
Ty1 epitope. Scale bar represents 10µm
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Supplementary Figure 10
Cell cycle status of T. brucei in co-infection with T. congolense or in a single species infection with
or without the induction of RNAi targeting TbHYP2.
T. brucei cells collected on day 8 of the experiment were scored for their kinetoplast and nuclear
configuration (>500 cells scored, n=3 for each condition tested). Error bars represent mean± SD.
There was a significantly higher proportion of 1K1N T. brucei cells when TbHYP2 RNAi was not
induced (-Dox), than when TbHYP2 RNAi was induced (+Dox) in a co-infection with T.
congolense (★★ p<0.01, One-way ANOVA with Tukey’s multiple comparisons test).
Supplementary Figure 11. 
Full length gels and blots from the Figures presented in this paper. 
a. Figure 2c blots
b. Figure 4 d blots
c. Supplementary Figure 4b blots
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